NX-5948 + fluconazole

**NX-5948 + fluconazole** is a combination regimen consisting of NX-5948, a novel oral small molecule Bruton’s tyrosine kinase (BTK) degrader, and fluconazole, a well-established oral antifungal agent commonly used for candidiasis and other fungal infections. NX-5948 selectively targets and promotes degradation of both wild-type and mutant BTK via the ubiquitin-proteasome pathway through recruitment to the cereblon E3 ligase complex, leading to reduced BTK protein levels and impaired B-cell receptor signaling, a key process in B-cell malignancies. The combination is being investigated specifically to characterize the pharmacokinetics (PK), drug-drug interactions, and safety profile of NX-5948 when co-administered with fluconazole in healthy volunteers. This is not a fixed-dose combination or co-formulated drug, but a regimen under clinical evaluation, primarily for drug-drug interaction and PK assessments[1][2][3][5][8].

Other names

NX-5948NX5948NX 5948fluconazole